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Abstract
Sei1 is a positive regulator of proliferation that promotes the assembly of Cdk4-cyclin D complexes and enhances the
transcriptional activity of E2f1. The potential oncogenic role of Sei1 is further suggested by its overexpression in various
types of human cancers. To study the role of Sei1, we have generated a mouse line deficient for this gene. Sei1-null
fibroblasts did not show abnormalities regarding proliferation or susceptibility to neoplastic transformation, nor did we
observe defects on Cdk4 complexes or E2f activity. Sei1-null mice were viable, did not present overt pathologies, had a
normal lifespan, and had a normal susceptibility to spontaneous and chemically-induced cancer. Pancreatic insulin-
producing cells are known to be particularly sensitive to Cdk4-cyclin D and E2f activities, and we have observed that Sei1 is
highly expressed in pancreatic islets compared to other tissues. Interestingly, Sei1-null mice present lower number of islets,
decreased b-cell area, impaired insulin secretion, and glucose intolerance. These defects were associated to nuclear
accumulation of the cell-cycle inhibitors p21Cip1 and p27Kip1 in islet cells. We conclude that Sei1 plays an important role in
pancreatic b-cells, which supports a functional link between Sei1 and the core cell cycle regulators specifically in the context
of the pancreas.
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Introduction
In mammalian cells, entry from quiescence into the cell cycle
and advance through G1 into S phase are controlled by the
activity of the D-type cyclin-dependent kinases Cdk4 and Cdk6
(Cdk4,6/D complexes) [1]. The expression of D-type cyclins in
response to extracellular mitogenic signals is tightly regulated at
different levels, as well as their binding to Cdk4,6. An important
level of regulation is exerted by the Cdk inhibitors (CKIs), which
include the Ink4 family (p16Ink4a, p15Ink4b, p18Ink4c and p19Ink4d)
and the Cip/Kip family (p21Cip1, p27Kip1 and p57Kip2) [2,3].
Once active, Cdk4,6/D complexes phosphorylate members of the
pocket protein family, namely, Rb, p107 and p130. These proteins
bind and inhibit transcription factors important for cell cycle
progression, most notably the E2f family of transcription factors,
whose target genes are necessary for the replication of the DNA
during S-phase. Upon phosphorylation, the pocket proteins are
released from the E2f transcription factors allowing them to
become transcriptionally active [4]. Alterations in the proteins that
regulate the early stages of the cell cycle, including Cdk4, D-type
cyclins and E2f1, have proven to be important in the development
of cancer [1]. At a more physiological level, Cdk4, D-type cyclins
and the E2f family have a clear impact in pancreas development
and homeostasis. Mice deficient for these proteins display
pancreatic abnormalities, mainly characterized by decreased
numbers of b-cells which result in insulin resistance and diabetes
[5-7]. Together, these observations indicate that b-cells are highly
sensitive to the activity of the Cdk4/cyclinD/E2f pathway [8].
Sei1, also known as Sertad1, belongs to the Sertad family of
proteins composed by four members named Sertad1-4 [9]. Sei1
binds to and stabilizes Cdk4/D complexes, stimulating their kinase
activity and preventing their inhibition by p16Ink4a [10,11]. Of
note, CKIs p21Cip1 and p27Kip1 also participate in the assembly
and stabilization of Cdk4/D complexes, as well as, in their nuclear
translocation [12,13]. However, it is still under debate whether the
Cdk4/D complexes associated to p21Cip1 or p27Kip1 are inactive
or may retain activity under particular conditions (discussed in
[14]). Independent studies on Sei1 and its closest homologue
Sertad2 have indicated that these proteins also promote
proliferation by binding to the transcription factor E2f1 and by
enhancing its transcriptional activity [15]. Together, these studies
suggest that Sei1 plays a positive role in cell cycle progression.
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Based on the positive role of Sei1 on Cdk4/D and E2f1
activities, it is conceivable that Sei1 could have a role in cancer
and/or pancreatic islet biology. With regard to cancer, amplifi-
cation of the genomic locus of Sei1 has been found in human head
and neck squamous cell carcinomas, ovarian carcinomas and
gastric carcinoma [16–18]. Here we have tested the current
models on Sei1 function by generating and analyzing Sei1-
deficient cells and mice.
Results
Sei1-Null Mice Are Viable and Have a Normal Longevity
The Sei1 gene is composed by two exons, the first one is non-
coding and the second one contains the complete open reading
frame. We engineered a gene-targeting vector that replaced exon 2
of Sei1 with a neomycin resistance cassette (Fig. 1A). Targeted ES
clones were confirmed by Southern blot analysis (Fig. 1B) and
were used to obtain Sei1-deficient mice (see below). In addition,
we generated Sei1-null ES cells by culturing Sei1-heterozygous ES
cells in medium with high neomycin concentrations (see Materials
and Methods; Fig. 1B). Complete Sei1 deficiency was corroborat-
ed by Northern blot analysis of Sei1-null ES cells (Fig. 1C) and
qRT-PCR from Sei1-deficient MEFs (Fig. 1D). Sertad2 is the
closest homolog of Sei1, and we wondered whether inactivation of
Sei1 had an impact on the expression of Sertad2 in MEFs.
Analysis of Sertad2 expression indicated that its levels remained
unchanged in Sei1-het and Sei1-null MEFs (Fig. 1D).
Homozygous Sei1-null mice were viable, fertile and showed no
overt pathologies. We checked the expression of Sei1 and Sertad2
in a variety of organs by qRT-PCR. Both Sei1 and Sertad2 were
expressed in most organs examined (Supp. Fig. S1). Detailed
histopathological analyses did not reveal abnormalities in Sei1-null
tissues (data not shown). When wt, Sei1-het and Sei1-null cohorts
of mice were aged, their survival curves were indistinguishable
(Supp. Fig. S2), as well as the pathologies observed in moribund
old mice (see below the incidence of spontaneous cancer).
Sei1-Null Cells Proliferate Normally
Mouse embryo fibroblasts (MEFs) were obtained from wild
type, Sei1-het and Sei1-null mice. First, we studied Cdk4
complexes in asynchronously growing cells, but we did not
observe differences in the abundance of Cdk4/D1 or Cdk4/D2
complexes (Fig. 2A and Supp. Fig. S3A). To check whether the
absence of Sei1 could affect the cell cycle, we rendered wt and
Sei1-null MEFs quiescent by serum withdrawal, and triggered cell
cycle re-entry by serum addition. As shown in Fig. 2B, Sei1-null
MEFs entered into S phase with normal efficiency and kinetics. As
a control, Cdk4-null MEFs presented a significant reduction in the
percentage of cells entering S phase, as previously reported [19].
To examine in further detail the cell cycle, we checked the
Figure 1. Generation of Sei1-deficient mice. (A) Strategy used to eliminate the second exon of Sei1, which contains the entire open reading
frame for Sei1. (B) Southern blot confirming the ablation of Sei1 alleles in ES cells. (C) Northern blot confirming the loss of Sei1 transcription in Sei1-
null ES. (D) Levels of Sei1 and Sertad2 transcripts in primary MEFs (n = 3, per genotype). Values correspond to average and s.d. of the levels relative to
actin.
doi:10.1371/journal.pone.0008744.g001
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phosphorylation of Rb during the first cell cycle after serum re-
addition, and observed no significant differences between wt and
Sei1-null cells (Fig. 2C and Supp. Fig. S3B). Finally, we also
assessed the activation of Cdk2 and, again, the kinetics and
intensity of activation of this kinase were similar across various
assays when comparing wt and Sei1-null MEFs (Fig. 2D and Supp.
Fig. S3C). To widen the scope of the previous analyses, we
checked cell cycle entry in splenocytes, which include both T- and
B-lymphocytes. These cells remain quiescent in culture until
activated with antigens. Sei1-null splenocytes entered proliferation
with kinetics and efficiencies indistinguishable from wt splenocytes
(Fig. 2E).
Sei1 has been also described as a positive co-factor for the
transcriptional regulator E2f1 [15]. We examined E2f1-driven
transcription using a luciferase reporter assay (based on the E2f1
promoter, [20]). However, the absence of Sei1 did not affect the
expression of luciferase by endogenous E2f1 levels (Fig. 3A) or by
overexpressed transfected E2f1 (Fig. 3B). Finally, we checked the
activity of E2f1 by measuring the expression of a well known E2f1
target, namely p19Arf [21]. Retroviral expression of E2f1 efficiently
upregulated p19Arf, but no differences were observed between wt
and Sei1-null cells (Fig. 3C). Also, under basal conditions the levels
of p19Arf were similar regardless of the Sei1 genotype (Fig. 3C).
All together, we conclude that the absence of Sei1 does not
affect significantly the cell cycle, neither in MEFs nor in
lymphocytes, and does not impair detectably the assembly of
Cdk4 complexes or the transcriptional activity of E2f1 in
fibroblasts.
Normal Immortalization and Oncogenic Transformation
of Sei1-Null Cells
Cell cycle regulators may have profound effects on the
susceptibility of cells to acquire oncogenic properties [1]. Thus,
we studied the serum dependence, immortalization and transfor-
mation capacity of MEFs deficient for Sei1. As shown in Fig. 4A,
Sei1-null MEFs proliferate at the same rate as wt MEFs under
different serum concentrations. When subjected to the 3T3 serial
passage protocol, we could not observe differences in the onset of
senescence or in the immortalization of wt and Sei1-null MEFs
(Fig. 4B). To further test this under more stringent conditions, we
seeded wt and Sei1-null cells at low cellular density and checked
for the appearance of colonies. Sei1-null MEFs showed the same
low colony formation capacity as wt MEFs, while Ink4a/Arf-
double null MEFs, used here as a positive control, formed colonies
efficiently (Fig. 4C). Finally, we examined the impact of Sei1
deficiency on the susceptibility of MEFs to neoplastic transforma-
Figure 2. Cell cycle of Sei1-null cells. (A) Cell extracts from asynchronously growing MEFs of the indicated genotypes were immunoprecipitated
using cyclinD1 or cyclinD2 antibodies, and then immunoblotted against Cdk4 to assess Cdk4-cyclinD complex formation. (B, C and D) MEF cultures of
the indicated genotypes were synchronized by serum withdrawal, and forced to re-enter the cell cycle by addition of serum to the medium. (B)
Percentage of cells in S phase was determined by the incorporation of propidium iodide and FACS analysis. The graph represents the average and s.d.
of at least two independent preparations of primary MEFs per genotype. ANOVA analysis (using Sidak multiple testing) indicated that Cdk4-null MEFs
were significantly different (p,0.05) than wt MEFs at all time points. Sei1-null MEFs only showed a significant difference with wt MEFs at time 8 h. (C)
Representative example of two experiments measuring Rb phosphorylation by immunoblotting protein extracts obtained at the indicated times. (D)
Representative example of at least two experiments assaying Cdk2 kinase activity from protein extracts of synchronyzed MEFs at the indicated times;
asynch.: MEFs asynchronously growing. (E) Splenocytes isolated from at least three mice per genotype were activated by LPS and concanavalin A, and
the number of lymphocytes was counted at the indicated times. Values correspond to the average and s.d.
doi:10.1371/journal.pone.0008744.g002
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tion by HRasG12V or by the combination of HRasG12V and E1A.
We measured the transformation efficiency by plating infected
cells at confluent density and counting the emergence of foci after
two weeks in culture. We could not observe differences between
Sei1-null and wt MEFs when subjected to these oncogenic
transformation assays (Fig. 4D). From these data we conclude
that the absence of Sei1 has no significant impact on the
requirement for external growth factors, ability to immortalize
spontaneously, or susceptibility to be oncogenically transformed.
Normal Apoptosis of Sei1-Deficient Cells
Based on the above negative data, we decided to expand our
studies to stress responses and apoptosis. First, we subjected wt and
Sei1-null MEFs to different doses of ultraviolet radiation, which
triggered the same levels of apoptosis in both genotypes (Fig. 5A).
Then, we infected Sei1-null MEFs with the oncoprotein E1A. This
oncoprotein sequesters and inhibits Rb [22] and induces a p19Arf/
p53-dependent apoptotic response [23]. As shown in Fig. 5B,
expression of E1A induced apoptosis in wt and Sei1-null MEFs to
similar levels, while p53-null MEFs were not affected. E1A
sensitizes MEFs to other apoptotic stimuli, such as serum
withdrawal or adriamycin [23]. However, Sei1-null MEFs infected
with E1A were as sensitive to serum withdrawal and adriamycin as
were wt MEFs (Fig. 5B). To extend our study to other cell types,
we irradiated mice with ionizing radiation and measured apoptosis
in thymocytes, however, there were no significant differences
between Sei1-null and wt thymocytes (Fig. 5C). Finally, we
analyzed the response of p53 and its target p21Cip1 to ionizing
radiation in the spleen and the lung. As observed in Fig. 5D, both
proteins, p53 and p21, were clearly induced upon irradiation but
this induction was not affected by the status of Sei1. Also, basal
levels of p21Cip1 and p53 were not detectably higher in Sei1-null
tissues compared to wt ones. We conclude that Sei1 does not have
a significant impact on the response of p53 to DNA damage and
the susceptibility to undergo apoptosis.
Sei1-Deficiency Does Not Impact on Tumor Development
in Mice
To address the impact of Sei1 on tumorigenesis, we first focused
on the emergence of spontaneous malignant tumors with aging.
Sei1-null mice developed spontaneous malignant tumors with the
same incidence and spectrum as wt mice (Fig. 6A). To further
explore this issue, we decided to subject our mice to carcinogenic
treatments. For this, we performed a carcinogenic assay that
consisted in intramuscular injection of 3-methyl-cholanthrene
(3MC), which results in the development of fibrosarcomas. We
could not observe significant differences between the onset of
fibrosarcomas in wt and Sei1-null mice (Fig. 6B). We then
Figure 3. E2f1 activity in Sei1-null cells. (A) Endogenous E2f1 activity was measured by transfecting at least three independent preparations of
primary MEFs per genotype with different amounts of a plasmid carrying the luciferase reporter under the regulation of the E2f1-responsive E2f1
promoter. Luciferase activity was measured two days after the transfection. Values represent the average and s.d. (B) Ectopic E2f1 activity was
measured as before after co-transfection with different amounts of a plasmid expressing E2f1. (C) Levels of protein p19Arf, a bona-fide E2f1 target,
were assessed by immunoblotting of extracts from MEFs of the indicated genotypes transduced with E2f1. These results were confirmed in another
independent assay. Actin was used as a loading control.
doi:10.1371/journal.pone.0008744.g003
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Figure 4. Proliferation, immortalization and transformation of Sei1-null MEFs. (A) Growth curves of primary MEFs grown at the indicated
serum concentrations. (B) Senescence and immortalization were evaluated performing a 3T3 serial passage protocol of MEFs of the indicated
genotype. DPDL, increase in population doubling level (C) Colony formation assay measuring the immortalization potential of MEFs of the indicated
genotypes. (D) Foci formation assay of MEFs transduced with HRasV12 or with bicistronic E1A/HRasV12. In all the above assays, at least three
independent preparations of primary MEFs per genotype were used. Values correspond to average and s.d.
doi:10.1371/journal.pone.0008744.g004
Figure 5. Apoptosis in Sei1-null cells. (A and B) Three independent preparations of primary MEFs per genotype were either irradiated with the
indicated doses of UVC (A), or transduced with E1A and treated with low serum conditions or with adriamycin, as indicated (B). Apoptosis was
measured by quantifying subG0 DNA content by FACS. (C) Thymocytes from three mice per genotype treated with 10 Gy of c-radiation were isolated
and apoptosis was measured 3 h post-radiation, as in (A) and (B). (D) Protein extracts of lung and spleen from the same irradiated mice as in (C) were
immunoblotted against p53 or its target p21Cip1. Actin was used as a loading control.
doi:10.1371/journal.pone.0008744.g005
Sei1 in Cancer and Diabetes
PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8744
performed a classical skin carcinogenesis protocol based on
initiation by DMBA and promotion by TPA. Again, Sei1-null
mice developed papillomas with similar kinetics and incidence as
wt mice (Fig. 6C). No significant differences could be observed
between the number of papillomas or their size; also no conversion
to carcinoma was observed in any genotype during the 34 weeks of
observation. In summary, Sei1-ablation does not seem to have a
major effect on the development of spontaneous or chemically-
induced tumors in mice.
Defective Pancreatic b-Cell Function in Sei1-Deficient
Mice
Genetic ablation of Cdk4 activity, cyclin D2, or combined E2f1
and E2f2, results in defective maintenance of adult pancreatic b-
cells, eventually resulting in severe diabetes [5–7]. Considering the
implication of Sei1 in the positive regulation of the above-
mentioned set of proteins (see Introduction), we wondered whether
Sei1-null mice could have mild, but detectable, defects in
pancreatic islets. For this, we first measured blood glucose levels
of wt, Sei1-het and Sei1-null mice during the first months of life,
but no significant differences were observed in basal glycemia
under conditions of ad libitum feeding (Fig. 7A). Interestingly, when
subjected to the glucose tolerance test, Sei1-deficient mice showed
a poorer clearance of glucose from blood compared to wt mice,
both under standard diet (Fig. 7B) or under high fat diet (Supp.
Fig. S4A). When insulin release was measured after injection of
glucose, Sei1-null mice showed a dramatically impaired secretion
of insulin to the bloodstream (Fig. 7C). Finally, sensitivity to insulin
was not altered in the absence of Sei1 (Supp. Fig. S4B). Together,
the above data point towards a specific defect in pancreatic b-cell
function in Sei1-null mice.
To further reinforce a role of Sei1 in b-cells, we evaluated the
expression of Sei1, Sertad2 and Sertad3 in isolated pancreatic
islets (being Sertad2 the closest paralog of Sei1). Interestingly, the
mRNA levels of Sei1, Sertad2 and Sertad3 were similar in wt
islets, and no compensatory changes in Sertad2 or Sertad3 were
observed in Sei1-null islets (Fig. 8A). As a control for the isolation
of islets, we detected the transcript for Kir6.2 (also known as
Kcnj11), which is expressed in the islets but not in the exocrine
pancreas [24] and no changes were observed associated to the
status of Sei1 (Fig. 8A). Of note, compared with a large set of
tissues (a total of 17 tissues), islets presented the highest levels of
Sei1 expression (Suppl. Fig. S1). Moreover, the ratio between the
levels of Sei1 and Sertad2 mRNAs was also maximal in the islets
(Suppl. Fig. S1). Therefore, it can be concluded that the levels of
Sei1 in islets are uniquely high.
In recent years, it has been established that Cdk4/cyclinD2
plays an important role in the maintenance of b-cells noticeable
after 3 months of age [5–7]. We wondered whether Sei1-null mice
could have a similar defect. We measured the size of the
pancreatic islets in 4- to 6-months old mice of wt, Sei1-null and
Cdk4-null genotypes. Interestingly, pancreatic islets of Sei1-null
Figure 6. Cancer susceptibility in Sei1-null mice. (A) Spontaneous cancer incidence and spectrum in old moribund mice (n = 15 for wt mice, and
n= 26 for Sei1-null mice). Presence and type of cancer was determined upon detailed histopathological analyses by one of the authors (J.M.F.).
Fisher’s exact test was used to determine statistical differences in total cancer incidence. (B) Latency of fibrosarcoma development after intramuscular
injection with 3MC represented by Kaplan-Meier curves (n = 16 for wt mice, and n=13 for Sei1-null mice). Statistical analysis was performed using the
Logrank test. (C) Papilloma latency, incidence and size after DMBA/TPA tumorigenesis in mice of the indicated genotypes (n = 14 per genotype). Bars
correspond to the s.d. of the average number of total papillomas per mouse. Student’s t-test was used to compare the two genotypes but no
significant differences were found.
doi:10.1371/journal.pone.0008744.g006
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mice showed a significant reduction in the number of pancreatic
islets (Fig. 8B), as well as, a decrease of approximately 50% in b-
cell area (Fig. 8C). The reduction in b-cell surface observed in
Sei1-null mice was of intermediate magnitude when compared
with the severe defect characteristic of Cdk4-null mice (Fig. 8C).
Sei1-null islets presented a normal architecture, with a-cells
predominantly located at the periphery of the islet and b-cells in
the core (see below Fig. 8F). In an effort to understand the
mechanisms that lead to decreased b-cell surface in the absence of
Sei1, we measured apoptosis and proliferation by TUNEL and
Ki67 immunohistochemistry, respectively, however the number of
positive islet cells for both markers was very low (,1%) and
quantifications could not detect significant differences between wt
and Sei1-null islets (data not shown). In an alternative approach,
immunohistochemical detection of the cell cycle inhibitors p21Cip1
and p27Kip1 revealed higher levels of positive nuclei in Sei1-null
pancreatic islets compared to wt islets (Fig. 8D–F). Interestingly,
the mRNA levels of p21Cip1 and p27Kip1 were similar in the islets,
as were the protein levels of p53 and p27Kip1 (Supp. Fig. S5).
These observations suggest that the increase in nuclei positive for
p21Cip1 and p27Kip1 is due to an altered balance in the subcellular
localization of these proteins. From these data, we conclude that
Sei1 plays a relevant role in the maintenance and function of
pancreatic b-cells. Absence of Sei1 results in higher levels of the
cell cycle inhibitors p21Cip1 and p27Kip1, reduced b-cell area,
decreased insulin secretion and, consequently, glucose intolerance.
Figure 7. Glucose homeostasis in Sei1-null mice. (A) Blood glucose levels were measured in groups of at least 4 male mice with the indicated
genotypes maintained under ad libitum feeding. (B) Glucose tolerance test (GTT) on male mice (n = 8 per genotype), of 8 weeks of age. The area under
the curve (AUC) for each genotype is represented to the right. (C) Insulin release test (IR) and its AUC performed in the same mice as in B (one week
after the GTT). Values correspond to the average and s.d. Statistical differences were determined by the Student’s t-test; *p,0.05; **p,0.01; and
***p,0.001.
doi:10.1371/journal.pone.0008744.g007
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Discussion
Sei1 has been involved in the positive regulation of the cell cycle
and proliferation [10,15–17] and, accordingly, its expression is
upregulated in several types of tumors [16,18,25]. Experimental
overexpression of Sei1 can provoke hyperproliferation [10],
genomic instability [17] and inhibition of apoptosis [26]. In an
effort to understand the role of Sei1 in the context of the organism,
here we have generated and characterized Sei1 deficient mice.
Experiments with primary fibroblasts and lymphocytes derived
from Sei1-null mice did not reveal any cellular or molecular
alteration regarding proliferation, immortalization, oncogenic
transformation, and apoptotic responses to DNA damage.
Furthermore, in the case of primary fibroblasts, Cdk4 complexes,
Cdk2 activity, Rb phosphorylation, E2f transactivation and p53
responses were normal in the absence of Sei1. At the organismal
level, Sei1-null mice were viable and showed no overt phenotypes,
including normal lifespan, spontaneous tumors and chemically-
induced tumors. The most probable explanation for this lack of
phenotypes is redundancy with other members of the Sertad
family that compensate for the absence of Sei1. Sertad2 is the
closest relative to Sei1 and, indeed, Sei1 and Sertad2 share
functional properties, including their ability to stimulate E2f1
activity [15]. Sei1 is also able to interact with Cdk4 and stimulate
Figure 8. Pancreatic islets in Sei1-null mice. (A) Levels of mRNA expression of the Sertad family members Sei1, Sertad2 and Sertad3, as well as,
the pancreatic islet gene Kir6.2, were measured using qRT-PCR in total mRNA from isolated pancreatic islets of wt (n = 4) and Sei1-null (n = 2) male
mice. (B–F) Paraffin sections of pancreas (n = 4 per genotype) of the indicated genotypes were stained with antibodies against insulin (B and C),
p27Kip1 (D) or p21Cip1 (E). (B) Number of islets relative to the total area of the pancreas. (C) Ratio between the b-cell islet area and the total pancreas
area. (D) p27Kip1- or (E) p21Cip1-positive nuclei relative to total b-cell area. (F) Representative examples of the indicated stainings. The dotted lines
mark the limits of the pancreatic islets. Values correspond to the average and s.d. Statistical differences were determined by the Student’s t-test;
*p,0.05; **p,0.01; and ***p,0.001.
doi:10.1371/journal.pone.0008744.g008
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its activity [10], although at present it remains unknown whether
this activity is shared or not with the other members of the Sertad
family.
A common feature of a number of mouse models deficient for
proteins in the Cdk4/cyclinD/E2f pathway is a defective glucose
homeostasis due to an impaired maintenance of pancreatic b-cells
[5–8]. The expression levels of Sei1, but not of Sertad2, are
maximal in pancreatic islets compared to any other tissue
examined (Supp. Fig. S1); and, moreover, Sertad2 and Sertad3
mRNA levels are not altered in Sei1-null pancreatic islets. All these
observations suggest that pancreatic islets could be more
particularly sensitive to the absence of Sei1. Interestingly, Sei1-
null mice displayed abnormal insulin secretion and blood glucose
clearance, as well as a reduction in pancreatic b-cell surface. In
addition, pancreatic islets of Sei1-null mice showed increased
nuclear staining of the cell cycle inhibitors p27Kip1 and p21Cip1.
These two cell cycle inhibitors have been implicated in the
negative control of b-cell mass [8]. In particular, overexpression of
p27Kip1 in islets results in decreased islet mass and diabetes [27].
Similarly, mice deficient in Skp2, which is responsible for the
normal degradation of p27Kip1, present ubiquitous higher levels of
p27Kip1, decreased b-cell mass and glucose intolerance, and all
these phenotypes are rescued in Skp2/p27Kip1-doubly deficient
mice [28]. At present, we do not know why p27Kip1 and p21Cip1
accumulate in the nuclei of Sei1-null b-cells. However, it is
tempting to speculate that the absence of Sei1 may increase the
availability of Cdk4/D complexes that can interact with p27Kip1 or
p21Cip1, thus increasing the amount of Cdk4/D/(p27Kip1-p21Cip1)
complexes, which normally reside in the nucleus [12,13]. Although
still under debate [29], recent evidence indicates that Cdk4/D/
(p27Kip1-p21Cip1) complexes are inactive [14] and this would be
consistent with the decreased islet size of Sei1-null mice.
We conclude that Sei1 ablation in mice does not affect tumor
growth, but the germline-based strategy followed in this work does
not preclude possible effects of acute Sei1 ablation in cancer
maintenance. As for the glucose homeostasis, our results suggest
that Sei1 may play an important role in diabetes or metabolic
disorders.
Materials and Methods
Ethics Statement
Mice were treated in accordance with the Spanish Laws and the
Guidelines for Humane Endpoints for Animals Used in Biomed-
ical Research, The Spanish National Cancer Research Center
(CNIO) is part of the ‘‘Carlos III’’ Health Institute (ISCIII) and all
protocols were previously subjected and approved by the Ethical
Committee of the ISCIII.
Generation of Sei1-Deficient Mice and Animal Care
Mice genetically deficient for Sei1 were produced using
standard procedures. The construct that eliminates exon 2 of
Sei1 (Fig. 1A) was linearized and electroporated into R1
embryonic stem (ES) cells (129Sv). One ES cell clone was used
to produce chimaeric male mice, which were crossed with Balb/c
females, and the progeny from this cross was genotyped by
Southern blotting. All the assays reported in Figs. 1–6 were
performed with mice of mixed genetic background Balb/c;129Sv
(50:50). All the assays reported in Figs. 7 and 8 were performed in
mice that had been backcrossed 9 times with C57BL/6 and
therefore had a .99.9% C57BL/6 genetic background. Animals
were housed at the CNIO, inside their corresponding pathogen-
free barrier areas. All mice were monitored twice per week, and
moribund mice were killed humanely. Tumors from non-autolysed
tissues were recovered from moribund or recently deceased mice.
Tissue samples were fixed in 10% buffered formalin, embedded in
paraffin wax, sectioned at 4 mm and stained with haematoxylin
and eosin (H&E) for a detailed histopathological analysis.
Antibodies
The antibodies used for immunoblotting and immunoprecipi-
tation were: Cdk4 (C-22, sc-260), Cdk2 (M-2, sc-163), cyclin D1
(C-20, sc-717), cyclin D2 (M-20, sc-593), p21Cip1 (C-19-G, sc-397-
G), and p19Arf (5-C3-1, sc-32748), all from Santa Cruz; and p53
(CM-5), from Novocastra. The antibodies used for immunohisto-
chemistry were: p21Cip1 (C-19-G, sc-397-G), from Santa Cruz;
p27Kip1 (DCS-72.F6), from Thermo Scientific; insulin (#A564),
from Dako; and glucagon (K79bB10), from Sigma Aldrich.
Cell Culture
MEFs were isolated from embryos at 13.5 days post-coitum
from crosses between Sei1(+/2) mice of mixed genetic back-
ground Balb/c;129Sv (50:50), and were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; GIBCO) supplemented with
10% Fetal Bovine Serum (FBS, Hyclone) and antibiotic/
antimycotic (GIBCO).
To obtain splenocytes and thymocytes, spleens were disaggre-
gated using a cell strainer (Nunc), and resuspended in complete
medium, comprising RPMI supplemented with 100 mM Hepes
buffer pH 7.5 (BioWhitaker), 2 mM L-Glutamine (GIBCO),
1 mM sodium pyruvate (GIBCO), a commercial mix of non-
essential amino acids (BioWhitaker), 0.1% b-mercaptoethanol
(Sigma) and antibiotic/antimycotic (GIBCO). Red blood cells
were lysed by incubating the preparation for 10 minutes at 4uC in
10 mM KHCO3, 150 mM NH4Cl, 0.1 mM EDTA pH 8, all
taken to pH 7.3. Thymocytes were frozen or processed for FACS
analysis at this point, whereas splenocytes were plated in complete
medium at a density of 26106 cells/ml, activated with 20 mg/ml
LPS and 5 mg/ml concanavalin A (Sigma), and counted at
different time points.
For cell cycle analysis, 26106 were plated in 10 cm diameter
dishes and left to reach confluency for 3 days; then, cells were
washed 3 times with PBS and cultured in medium without serum
for another 3 days. After this time medium with 10% FBS was
added, and cells were processed for FACS analysis or protein
extraction at different times.
For luciferase assays, cells were transfected with pGL3-Basic
(Promega) without promoter (basal transcription control) or with
the human E2f1 promoter cloned upstream the luciferase reporter.
pBabe-E1Fa-Renilla was used as an internal transfection control.
Two days later cells were processed using the Dual Luciferase
Assay System (Promega) following the manufacturer’s instructions,
and firefly and Renilla luciferase activities were measured in a
luminometer Glomax (Promega). Firefly luciferase values were
normalized to the Renilla control values.
For growth curves, 1.56105 cells were plated in 35 mm
diameter multiwell plates, cultured in media with different serum
concentrations and counted 4 hours later (time point 0), or 2, 4 or
7 days after plating.
Serial 3T3 cultivation was done as described [30]. Briefly, 106
cells were plated on 10 cm diameter dishes, 3 days later the total
number of cells in the dish were counted, and 106 cells were
replated again. This procedure was repeated for 40 passages. The
increase in population doubling level (DPDL), was calculated
according to the formula DPDL= log(nf/n0)/log2, where n0 is the
initial number of cells and nf is the final number of cells.
Colony and foci formation assays were performed as described
elsewhere [31]. For colonies formation, 66103 cells were
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distributed on a total of three dishes of 10 cm diameter and
incubated in DMEM plus 10% FBS. After 2 weeks of incubation
with regular changes of medium every 3 days, dishes were stained
with Giemsa, and the number of visible colonies (.1.5 mm of
diameter) was scored.
For foci formation, early-passage MEFs (P0-P1) derived from
individual embryos were seeded (106 cells) in plates of 10 cm
diameter and cultured overnight in complete medium containing
10% FBS. The medium was changed 1 h before transfections
began. For these assays, we used oncogenic H-rasV12 under an
LTR promoter in vector pBabe-puro. Transfections were done by
a standard calcium-phosphate procedure with 10 mg of pBabe-
puro-H-rasV12 plus 20 mg of carrier DNA plasmid (empty
pBabe-puro). After 8 h of incubation with the precipitates, the
incubation medium was changed and, 18 h later, cells were
distributed equally into three 10 cm diameter plates. Dishes were
refed with fresh medium every 3 days. At day 21 post-transfection,
cells were fixed and stained with Giemsa, and the total number of
foci in the three plates was scored.
For retroviral transduction, plasmids indicated in each exper-
iment were co-transfected along with pCL-Eco (to produce the
ecotropic variant of the Moloney murine leukemia virus) into
293T cells using Fugene 6 (Roche) as reagent, following the
manufacturer’s instructions. After two days the supernatant
containing the viral particles was filtered by 45 mm pore-filters,
mixed with polybrene to a final concentration of 4mg/ml and
added to 10 cm diameter plates with the recipient MEFs. This
process was repeated three more times, after which infected MEFs
were cultured for 2 days in medium with 2 mg/ml puromycin for
selection of the infected cells.
For induction of apoptosis, cells were either washed twice with
PBS and irradiated with a UVC irradiator (Hoeffer) or transduced
with viral E1A and subjected to low serum concentration or 0.2 or
0.05 mg/ml adriamycin for two days, after which they were
processed for FACS analysis.
FACS Analysis
Cells were trypsinized and resuspended in cold PBS. Cold
ethanol was added dropwise under constant agitation to this cell
suspension until reaching a 70% final concentration, and the
preparation was kept at 4uC for one to 7 days. These cells were
resuspended in PBS containing 30 mg/ml of propidium iodide
(Sigma) and 0.1 mg/ml RNase (Invitrogen), incubated at 37uC
for 30 minutes, and analyzed by flow cytometry using
FACScalibur (BD Biosciences). CellQuest Pro (BD Biosciences)
software was used to measure subG0 apoptotic bodies, and the
Modfit (Verity Software House) software to obtain cell cycle
profiles.
Immunoprecipitations and Kinase Assays
Protein lysates obtained with the NP-40 buffer (0.5% NP-40,
1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 10 mM
phosphate buffer pH 7.2) were pre-cleared by incubating them
with protein A or G (Santa Cruz). Supernatants were incubated
O/N at 4uC with 5–10 mg antibodies against cyclin D1, cyclin D2
or Cdk2 using orbital agitation, after which protein A or G was
added and the mix was incubated at 4uC for 2 hours. Supernatant
was kept for the loading control, and the beads were washed three
times with the NP-40 buffer. For the IPs, the beads were
resuspended in 50 ml of Laemmli buffer, boiled for 5 minutes and
immunoblotted using an antibody against Cdk4. For the Cdk2
kinase assays, the beads were washed three times with the kinase
assay buffer (20 mM Tris-HCl pH 8; 10 mM MgCl2; 1 mM
EGTA; 1 mM DTT; 1 mM PMSF; 1 mM Na3VO4; 1 mM NaF
and a cocktail of protease inhibitors (Roche)). The beads were
then incubated with a mix of 20 ml of the kinase buffer, 5 mg
of histone H1 (Boeringer), 1 ml of 0.5 mM cold ATP and 10 mCi
of c32P-ATP at 30uC for 30 minutes, mixed with 100 ml of
Laemmli loading buffer, loaded into a gel and developed by
autoradiography.
Quantitative RT-PCR
Quantitative PCRs of the indicated genes was performed using
the 7900Fast qRTPCR system (Applied Biosystems), and data
were analyzed using the SDS software provided with it. The
oligonucleotides used were the following (listed 59 -.39): Sertad1:
sense, CAAGCGGGAGGAGGAGGAGACGAT; antisense, AG-
AAGGGGCTGGGGGCTGGAT; Sertad2: sense, CGCACA-
GATGACTCACGATT; antisense, GGGGTCAAAATCGTA-
CATGG; Sertad3: sense, CAGGCTTGTCGGAGGTAGTC;
antisense, TTGGACTCCAGTCCCACTTC; Kir6.2: sense,
AGAATATCGTCGGGCTGATG; antisense, CTCTTTCGGA-
GGTCCCCTAC; actin, sense, GGCACCACACCTTCTACA-
ATG; antisense, GTGGTGGTGAAGCTGTAGCC.
Chemical Carcinogenesis
For induction of fibrosarcomas, mice of 3–5 months received
1 mg of 3-methyl-cholanthrene (Sigma-Aldrich) in 50 ml of sesame
oil by intramuscular injection in the right leg. Mice were examined
twice per week until the tumor was palpable and scored in Kaplan-
Meier graphs.
For induction of papillomas, mice of 2–4 months received a
single dose of 20 mg DMBA dissolved in 200 ml of acetone in their
shaved backs. Five days later started the treatment with 12.5 mg of
TPA dissolved in 200 ml of acetone twice a week for 19 weeks. The
number of papillomas was counted, and their size measured with a
Vermier caliber during 34 weeks.
Glucose Homeostasis and Analysis of Pancreatic Islets
To measure pancreatic islets, paraffin sections of pancreas
were stained with an insulin antibody (DAKO), and the surface
ratios of b-pancreatic islets versus total pancreas were
measured using a Mirax scan, and analyzed using the
AxioVision software, both from Zeiss. To measure glucose
levels, blood samples from male mice fed ad libitum were
analyzed for their glucose content using Glucocard Memory 2
Base (A. Menarini Diagnostics). For the high fat diet, mice
were fed with Research Diets 12451, 45% kJ from fat, during
two months. For the glucose tolerance test (GTT), insulin
tolerance test (ITT) and insulin release (IR) assays, groups of
wt or Sei1-null males (n = 8 per genotype) of 9 weeks of age
were used and all the assays begun after overnight starvation.
For the GTT, mice were injected intraperitoneally with a 50%
solution of dextrose in PBS and a total amount of 2 g of
dextrose per Kg of mouse weight, and blood glucose was
measured at 0, 15, 30, 60, 90 and 120 minutes. For the ITT
assay, mice were injected with 0.75 U/Kg insulin in saline,
and blood glucose was measured at 0, 15, 30, 45, 60 and 90
minutes. For the IR assay, mice were injected with 3 g/Kg
dextrose in PBS, and blood samples were obtained at 0, 2, 5,
15 and 30 minutes. Serum from these samples were analyzed
for their insulin content using the Ultra Sensitive Mouse
Insulin ELISA Kit (Crystal Chem Inc) and blood glucose was
also monitored to control that the assay was correctly
performed.
Pancreatic islets were isolated following standard methods,
essentially as described in [32].
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Statistics
Data are presented as mean and standard deviation. Unless
otherwise stated, statistical analyses were performed using
unpaired Student’s t-test. Differences were considered statistically
significant at p,0.05. The following symbols are used: *p,0.05;
**p,0.01 and ***p,0.001.
Supporting Information
Figure S1 Tissue distribution of Sei1 and Sertad2 expression.
(Top) Total RNA from a panel of mouse organs was isolated and
analyzed by qRT-PCR for the expression of Sei1 relative to actin.
(Middle) Sertad2 mRNA levels analyzed as before relative to actin.
(Bottom) Ratio between Sei1 and Sertad2 expression levels.
Found at: doi:10.1371/journal.pone.0008744.s001 (0.40 MB TIF)
Figure S2 Survival curves of Sei1-null mice. Cohorts of 17 males
and 16 females for the wt group, and 22 males and 23 females for
the Sei1-null group, were aged until signs of terminal morbidity.
Data are represented as Kaplan-Meier curves. Logrank test
indicated that differences were not statistically significant.
Found at: doi:10.1371/journal.pone.0008744.s002 (0.57 MB TIF)
Figure S3 Cell cycle of Sei1-null cells. (A) Quantification of the
experiment shown in main Fig. 2A (n= 2). (B) Quantification of
the experiment shown in main Fig. 2C (n= 2). (C) Quantification
of the experiment shown in main Fig. 2D (n = 2) Values
correspond to the average and s.d. Student’s t-test was used to
compare the two genotypes but no significant differences were
found.
Found at: doi:10.1371/journal.pone.0008744.s003 (0.29 MB TIF)
Figure S4 Pancreatic function of Sei1-deficient mice. (A)
Glucose tolerance test (GTT) performed in male mice (n = 8 per
genotype) after two months feeding with a high fat diet. The area
under the curve (AUC) is represented to the right. (B) Insulin
tolerance test (ITT) performed in the same mice of Figure 7B and
7C of the main paper.
Found at: doi:10.1371/journal.pone.0008744.s004 (0.26 MB TIF)
Figure S5 Levels of cell cycle regulators in Sei1-null pancreatic
islets. Islets were isolated from wt and Sei1-null mice (n = 3 for
each genotype) and each individual preparation was analyzed
separately. RNA levels were measured by quantitative real-time
PCR and protein levels by immunoblot (the inset shows one
example per genotype). Student’s t-test was used to compare the
two genotypes but no significant differences were found.
Found at: doi:10.1371/journal.pone.0008744.s005 (0.32 MB TIF)
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